Working with the NCL
Input of Nanomaterials - Evaluation Criteria - Intellectual Property - Education & Training Application Process - Assay Cascade - NCL Nanoparticles - Material Transfer Agreement Assay Cascade Protocols
|
Physico-Chemical Characterization | Method ID | ||||
Size, Size Distribution |
|||||
Measuring the Size of Nanoparticles in Aqueous Media Using Batch-Mode DLS | NIST-NCL PCC-1 | ||||
Topology Molecular Weight Aggregation Purity Chemical Composition Surface Characteristics Functionality Zeta Potential Stability Solubility |
|||||
In Vitro | Method ID | ||||
Sterility | |||||
Endotoxin | STE-1 | ||||
Bacterial/Yeast/Mold | STE-2 | ||||
Mycoplasma | STE-3 | ||||
Targeting | |||||
Cell Binding/Internalization | |||||
In Vitro Immunology |
|||||
Blood Contact Properties | |||||
Plasma Protein Binding (2D PAGE) | ITA-4 | ||||
Hemolysis | ITA-1 | ||||
Platelet Aggregation | ITA-2 | ||||
Coagulation | ITA-12 | ||||
Complement Activation | ITA-5 | ||||
Cell-Based Assays |
|||||
CFU-GM | ITA-3 | ||||
Leukocyte Proliferation | ITA-6 | ||||
Macrophage/Neutrophil Function (4 categories): | |||||
Phagocytosis | ITA-9 | ||||
Cytokine Induction (6 assays): TNFα, IL-1β, IL-6, IL-8, IL-10, IL-12 | ITA-10 | ||||
Chemotaxis | ITA-8 | ||||
Oxidative Burst (NO) | ITA-7 | ||||
Cytotoxic Activity of NK Cells | ITA-11 | ||||
Toxicity | |||||
Phase I/II Enzyme Induction/Supression | |||||
Oxidative Stress | |||||
GSH Homeostasis (HEP G2) | GTA-3 | ||||
Lipid Peroxidation (HEP G2) | GTA-4 | ||||
ROS | GTA-7 | ||||
Cytotoxicity (necrosis) | |||||
MTT and LDH Release (porcine renal proximal tubule cell) | GTA-1 | ||||
MTT and LDH Release (HEP G2) | GTA-2 | ||||
Cytotoxicity (apoptosis) | |||||
Caspase 3 Activation (porcine renal proximal tubule cell) | GTA-5 | ||||
Caspase 3 Activation (HEP G2) | GTA-6 | ||||
Metabolic Stability | |||||
CYP450 (Phase 1) | |||||
Glucuronidation, Sulphation (Phase II) | |||||
In Vivo |
|||||
Initial disposition study | |||||
Tissue Distribution | |||||
Clearance | |||||
Half-life | |||||
Systemic exposure (plasma AUC) | |||||
Immunotoxicity | |||||
28 day screen | |||||
Immunogenicity (repeat-dose tox study) | |||||
Dose -Range Finding Toxicity | |||||
Blood Chemistry | |||||
Hematology | |||||
Histopathology | |||||
Gross Pathology | |||||
Efficacy | |||||
Therapeutic | |||||
Imaging | |||||
GLP Studies | |||||
PK/ADME | |||||
Expanded Single Dose Acute Tox |
A Service of the National Cancer Institute |